Akers Biosciences and Premas Biotech Announce Initiation of Animal Studies
July 07 2020 - 9:00AM
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer
of rapid health information technologies, today announced with its
partner, Premas Biotech, the initiation of animal studies for its
SARS-CoV-2 vaccine candidate in India. Premas has successfully
completed the manufacturing process for the VLP (virus like
particle) vaccine candidate, including three antigens from
SARS-CoV-2. The 4-week test is expected to be placebo controlled,
blinded, and randomized, in mice. The test will first seek to
evaluate safety in the rodent model and secondly examine immune
response dose titration. Premas plans to administer the test across
different dose amounts, including amounts that would be applicable
to humans.
Prabuddha Kundu, Co-Founder and Managing
Director at Premas Biotech, commented, “We are excited that we have
been able to manufacture and characterize the VLP containing three
main proteins from the SARS-CoV-2 virus. We are now moving ahead
for this animal study using mice to analyze safety and
immunogenicity of the candidate. We believe it will be first case
of a three antigen VLP being dosed in an animal for SARS
CoV-2.”
Premas is also currently engaged in
communications with regulatory authorities in both India and the
United States. Data from this study is expected in approximately
six weeks.
Concurrently with the initiation of this trial,
Akers has determined that it will cease shipping its PIFA Heparin /
Platelet Factor 4 Rapid Assay products and will no longer focus on
the development, manufacture, and supply of rapid, point of care
screening and testing products.
Christopher Schreiber, Executive Chairman of
Akers, stated, “The initiation of animal studies is an important
milestone for us with our partner, Premas. Concurrently with the
initiation of this trial, the board of Akers believed it would be
in the best interest of stockholders to cease Akers’ screening and
testing products line of business and to focus its resources on
other strategic priorities that are currently being evaluated.”
About Premas Biotech
Premas Biotech develops novel &
transformational technologies and partners with global
biopharmaceutical companies to build and develop novel
biotherapeutic & vaccine candidates. Premas' key focus areas
are infectious diseases, cancer, metabolic disorders
and inflammation. Besides D-CryptTM the difficult to express
proteins expression platform, Premas’ leading technologies include
Axtex-4D™: an ex-vivo tissueoid generation platform and C-Qwence™:
a fully human naive India based scFv antibody library. Further
information is available on the Company’s
website: www.premasbiotech.com
Contact email: contact@premasbiotech.com
About Akers Biosciences
Inc.
Akers Biosciences is pursuing the development of
a recently acquired license to a coronavirus vaccine candidate.
Akers has also previously announced that that it
had identified the hemp and minor cannabinoid sectors as
promising adjacent opportunities that could benefit from Akers’
existing facility and its core competencies.
Additional information on the company and its products can be
found at www.akersbio.com.
Forward Looking Statements
Certain statements in this press release that
are forward-looking and not statements of historical fact are
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements of historical fact, and may be identified by words such
as “anticipates,” “assumes,” “believes,” “can,” “could,”
“estimates,” “expects,” “forecasts,” “guides,” “intends,” “is
confident that”, “may,” “plans,” “seeks,” “projects,” “targets,”
and “would,” and their opposites and similar expressions are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management
as well as assumptions made by and information currently available
to management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of
certain factors, including, but not limited to, market and other
conditions, changes in the market acceptance of the company’s
products and services; challenges we may face in identifying,
acquiring and operating new business opportunities; the outcome of
litigation or other proceedings to which the company is subject or
which it may become subject to in the future; increased levels of
competition; changes in political, economic or regulatory
conditions generally and in the markets in which the company
operates; the company’s relationships with its key customers;
adverse conditions in the industries in which the company’s
customers operate; the company’s ability to retain and attract
senior management and other key employees; the company’s ability to
quickly and effectively respond to new technological developments;
the company’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on the
company’s proprietary rights; the company’s ability to achieve the
expected benefits and costs of the transactions related to the
acquisition of Cystron Biotech, LLC, including, the timing of, and
the company’s ability to, obtain and maintain regulatory approvals
for clinical trials of the company’s vaccine product candidate, the
timing and results of the company’s planned clinical trials for its
vaccine product candidate, the amount of funds the company requires
for its vaccine product candidate, and the company’s ability to
maintain its license with Premas Biotech PVT Ltd; and the impact of
the recent COVID-19 outbreak on the company’s results of
operations, business plan and the global economy. A discussion of
these and other factors, including risks and uncertainties with
respect to the company, is set forth in the company’s filings with
the SEC, including its annual report on Form 10-K filed with the
Securities and Exchange Commission, as may be supplemented or
amended by the company’s Quarterly Reports on Form 10-Q. The
company disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Contact:
Investor Relations: Hayden IRBrett Mass,
Managing PartnerPhone: (646) 536-7331Email:
brett@haydenir.comwww.haydenir.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024